Last reviewed · How we verify
Fluzone HD IIV
At a glance
| Generic name | Fluzone HD IIV |
|---|---|
| Sponsor | FluGen Inc |
| Modality | Biologic |
| Phase | Phase 1 |
Approved indications
Common side effects
Key clinical trials
- High vs. Standard Dose Influenza Vaccine in Adult SOT Recipients (PHASE2)
- Study to Evaluate Immunogenicity and Safety of a High-Dose Influenza Vaccine in Adults 50 Through 64 Years of Age (PHASE3)
- High vs. Standard Dose Influenza Vaccines in Lung Transplant (Repeater) (PHASE2)
- Immunogenicity of Influenza Vaccinations (PHASE4)
- Study of a Combination Vaccine Comprised of Different Recombinant Spike Antigen Levels of a Matrix-M Adjuvanted Recombinant COVID-19 Vaccine and High-Dose Inactivated Influenza Vaccine in Adult Participants 50 Years of Age and Older (PHASE1, PHASE2)
- Comparison of Recombinant Influenza Vaccine Versus Standard Egg-Based Inactivated Influenza Vaccine in Adults 18-64 Years (PHASE4)
- The Effects of Attenuated Versus Inactivated Flu Vaccine in Twin Sets (PHASE1)
- Response to Inactivated Influenza Vaccine in Lymph Tissue and Blood (PHASE4)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Fluzone HD IIV CI brief — competitive landscape report
- Fluzone HD IIV updates RSS · CI watch RSS
- FluGen Inc portfolio CI